Potentiating antitumor immunity is a promising therapeutic approach for treating a variety of
cancers, including
breast cancer. One potential strategy to promote antitumor immunity is targeting DNA damage response. Given that the
nuclear receptor NR1D1 (also known as REV-ERBĪ±) inhibits DNA repair in
breast cancer cells, we explored the role of NR1D1 in antitumor CD8+ T-cell responses. First, deletion of Nr1d1 in MMTV-PyMT transgenic mice resulted in increased
tumor growth and lung
metastasis. Orthotopic allograft experiments suggested that loss of Nr1d1 in
tumor cells rather than in stromal cells played a prominent role in increasing
tumor progression. Comprehensive transcriptome analyses revealed that biological processes including type I IFN signaling and T cell-mediated immune responses were associated with NR1D1. Indeed, the expression of type I IFNs and infiltration of CD8+ T cells and natural killer cells in
tumors were suppressed in Nr1d1-/-;MMTV-PyMT mice. Mechanistically, NR1D1 promoted DNA damage-induced accumulation of cytosolic
DNA fragments and activated cGAS-
STING signaling, which increased the production of type I IFNs and downstream
chemokines CCL5 and CXCL10. Pharmacologic activation of NR1D1 by its
ligand,
SR9009, enhanced type I IFN-mediated antitumor immunity accompanied by the suppression of
tumor progression and lung
metastasis. Taken together, these findings reveal the critical role of NR1D1 in enhancing antitumor CD8+ T-cell responses, suggesting that NR1D1 may be a good therapeutic target for
breast cancer.
SIGNIFICANCE: